drugset / Trial / NCT03138408
SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a two-part study consisting of Part A (dose regimen finding) followed by Part B (dose expansion). Part A (dose regimen finding) will allow definition of the maximum tolerated dose (MTD) through dose escalation and possible dose interval modification. In Part B (dose expansion), potential therapeutic doses may be studied with SC-004 as monotherapy and SC-004 in combination with ABBV-181 in disease-specific cohorts.
Timeline
- Start
- 2017-06-14
- Primary completion
- 2019-05-02
- Completion
- 2019-05-02
Outcome
Outcome not reported
Stopped (Business): “Strategic considerations”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Budigalimab | Monoclonal antibody | — | Intravenous |
| Subject | SC-004 | Unknown | — | Intravenous |